Heart failure & cardiomyopathies
Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial
Authors' conclusion
The efficacy of vericiguat was consistent across background therapy with very high adherence to guidelines accounting for patient-level indications, contraindications, and tolerance.
Study context
- Population
- Patients with HFrEF enrolled in VICTORIA5,040 with baseline medication data
- Participants
- 5,050 patients
- Comparison
- Vericiguat vs placebo, by adherence to guideline-directed medical therapy
- Primary endpoint
- CV death or HF hospitalization, by background guideline-directed medical therapy adherence
Methodological detailsmultivariable adjustment
- Multivariable adjustment
Primary result
As reported in the abstract
Vericiguat treatment effect across adherence-to-guidelines groups
- Treatment effect of vericiguat consistent across adherence groups (basic or dose-corrected), with or without multivariable adjustment; no treatment heterogeneity
Further findings
Baseline adherence to guidelines (basic / indication-corrected / dose-corrected)
- ACEi/ARB/ARNI
- 87.4% / 95.7% / 50.9%
- Beta-blockers
- 93.1% / 96.2% / 45.4%
- MRA
- 70.3% / 87.1% / 82.2%
- Triple therapy (ACEi/ARB/ARNI + beta-blocker + MRA)
- 59.7% / 83.3% / 25.5%
Original publication
Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial. Circ Heart Fail. Published 7 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →